Switching anti-CGRP monoclonal antibodies in chronic migraine: real-world observations of erenumab, fremanezumab and galcanezumab.

Jamie TalbotRebecca StuckeyNatasha WoodAlexander GordonGinette CrossinghamStuart Weatherby

Published in: European journal of hospital pharmacy : science and practice (2024)

We recorded modest improvements in headache outcomes, although significant results were only observed in those that switched anti-CGRP-mAb due to ineffectiveness. Switching may therefore be a viable option for these individuals.

Keyphrases

type diabetes
metabolic syndrome
monoclonal antibody
insulin resistance
adipose tissue
skeletal muscle